Abstract
BackgroundCompression therapy is an essential part of chronic venous disorder (CVD) treatment in reducing associated complications. This observational study aimed to note the use, effects and tolerance of a mobile intermittent pneumatic calf compression (IPC) device, Vekroosan® (DVT Solution P/L).MethodsIn 56 patients, Doppler ultrasonography was used to measure venous blood peak flow velocity (PFV) at external iliac, common femoral, distal superficial femoral and popliteal vein levels both before and after application of Vekroosan calf compressor for comparison.ResultsVekroosan was able to show significant clinical benefit in 45 patients (80%). There was a significant increase in femoral PFV pressure in post-compression measurement when compared to the pre-compression measurement (43.1 vs. 32.4 cm/s, P < 0.001), even when patients mobilize. On average, the PFV pressure increased by 10.7 cm/s when compared to baseline. A significant decrease was seen in calf swelling after calf compression (31.3 vs. 21.9 cm, P < 0.01), also with mobilization. Eighty-seven percent of patients tolerated the device well.ConclusionsOur study shows that use of mobile IPC devices, such as Vekroosan, is safe and effective in the treatment of CVD, can be used while mobilizing and can achieve results comparable to non-mobile devices.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
